All In MedTech

FDA Clearance Tracker · P160045-S034

Oncomine Dx Target Test

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jan 21, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jan 21, 2022

Approved

Time to decision

29 days

Received Dec 23, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P160045-S034
Device name
Oncomine Dx Target Test
Applicant location
Carlsbad, CA
Received
Dec 23, 2021
Decided
Jan 21, 2022
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P160045

Device type

Device class
Class III

Every decision under product code PQP

FDA's approval statement

As written in FDA's record.

Approval of the clinical protocol titled Oncomine Dx Target Test Clinical Validation Protocol: Biomarker EGFR Exon 20 Insertions (Olympic) - PRJ0002127 Supplemental Sample Study, for the post-approval study (PAS) protocol.

Source documents

Other decisions for Life Technologies Corporation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.